Dr. Wei Liu
Neurology (Vascular Neurology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 121
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Vascular Neurology Physician primary
KY license 44225 -
Diagnostic Neuroimaging (Radiology) Physician
IA license 38132 -
Neurology Physician
AZ license 81035 -
Neuroradiology Physician
IA license 38132 · KY license 44225 -
Vascular & Interventional Radiology Physician
IA license 38132
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 121
- Services billed
- 223
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 95 | 49 |
| Established patient office or other outpatient visit, 30-39 minutes | 82 | 66 |
| Established patient office or other outpatient visit, 40-54 minutes | 59 | 50 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 39 | 22 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 15 | 11 |
| Insertion of tube into intracranial artery for diagnosis or treatment with review by radiologist | 15 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 12 | 12 |
| Insertion of tube into brain artery for diagnosis or treatment with review by radiologist | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Louisville, KY | 125 |
| Atorvastatin Calcium Other prescribers in Louisville, KY | 73 |
| Pantoprazole Sodium Other prescribers in Louisville, KY | 73 |
| Amlodipine Besylate Other prescribers in Louisville, KY | 57 |
| Gabapentin Other prescribers in Louisville, KY | 55 |
| Rosuvastatin Calcium Other prescribers in Louisville, KY | 48 |
| Lisinopril Other prescribers in Louisville, KY | 42 |
| Eliquis (apixaban) Other prescribers in Louisville, KY | 41 |
| Memantine Hcl Other prescribers in Louisville, KY | 39 |
| Xarelto (rivaroxaban) Other prescribers in Louisville, KY | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $132 in total to this clinician.
| Medtronic, Inc. | $132 |
|---|
| Food and Beverage | $132 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $6,614 in research payments for these studies, mostly to the institutions running them.
- A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
AbbVie Inc. · Completed · NCT04309474 - M19-148 - A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.